|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 7, 12, 1 and 1 respectively.
Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hospital-acquired-pneumonia-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease) .
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001884131/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Achaogen Inc
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Cardeas Pharma Corp
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Lakewood-Amedex Inc
MedImmune LLC
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics AG
Polyphor Ltd
Sealife PHARMA GMBH
Shionogi & Co Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001884131/discount
List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP) , H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
Products under Development by Companies, H2 2017 (Contd..2) , H2 2017
Products under Development by Companies, H2 2017 (Contd..3) , H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001884131/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
